Sherene Loi, MD, PhD, on Triple-Negative Breast Cancer: Phase II Study Results of Nivolumab, Carboplatin, and Paclitaxel

0 seconds of 0 secondsVolume 90%

00:00

Sherene Loi, MD, PhD, on Triple-Negative Breast Cancer: Phase II Study Results of Nivolumab, Carboplatin, and Paclitaxel

2023 SABCS

Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses recent data showing that for patients with stage I/II triple-negative breast cancer, 12 weeks of a neoadjuvant nonanthracycline chemotherapy regimen with nivolumab may be efficacious with either concurrent or lead-in nivolumab. Those with immune-enriched tumors had high pathologic complete response rates, identifying a subpopulation for whom a 12-week anthracycline-free chemotherapy regimen with nivolumab may be appropriate (Abstract LBO1-03).

Hope S. Rugo, MD, on Triple-Negative Breast Cancer: Trial Update on Pembrolizumab Plus Olaparib vs Pembrolizumab Plus Chemotherapy

Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses data from the phase II KEYLYNK-009 study, which compared pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (Abstract GS01-05).

Breast Cancer

The ASCO Post Staff

Aditya Bardia, MD, MPH, on Early-Stage, High-Risk Breast Cancer: New Data on Pembrolizumab Plus Chemotherapy

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses phase III findings from the KEYNOTE-756 study, which showed that adding pembrolizumab to chemotherapy increases the pathologic complete response rate and lowers the residual cancer burden in patients with early-stage, high-risk ER-positive or HER2-negative breast cancer (Abstract GS01-02).

Breast Cancer

The ASCO Post Staff

Amy Tiersten, MD, on Metastatic Breast Cancer: A Possible Chemotherapy-Free Front-Line Regimen

Amy Tiersten, MD, of the Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses findings from the ASPIRE trial, which showed the combination of anastrozole, palbociclib, trastuzumab, and pertuzumab in the front-line setting was well tolerated and effective, with a clinical benefit rate of 97% in patients with previously untreated hormone receptor–positive, HER2-positive metastatic breast cancer (Abstract RF02-01).

Breast Cancer

The ASCO Post Staff

Daniel Kates-Harbeck, MD Candidate, and Nadia Harbeck, MD, PhD, on Personalizing Breast Cancer Management With AI: Novel Approach to Predicting Outcomes

Nadia Harbeck, MD, PhD, of LMU University Hospital and Ludwig Maximilian University of Munich, and Daniel Kates-Harbeck, of the West German Study Group and an MD Candidate at Ludwig Maximilian University of Munich, discuss a learning-based neural network developed by Mr. Kates-Harbeck to predict treatment outcomes in early breast cancer as well as potentially other tumor types (Abstract PO 04 1-10).

Breast Cancer

The ASCO Post Staff

Senthil Damodaran, MD, PhD, on Locally Advanced or Metastatic Breast Cancer: Phase II Results on Futibatinib

Senthil Damodaran, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses final results from the FOENIX-MBC2 study of the efficacy and safety of futibatinib in patients with locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring high-level FGFR1 gene amplification. Futibatinib plus fulvestrant showed antitumor activity in those whose disease had progressed on prior CDK4/6 inhibitors (Abstract RF01-04).

Apr

Today In Oncology

Sherene Loi, MD, PhD, on Triple-Negative Breast Cancer: Phase II Study Results of Nivolumab, Carboplatin, and Paclitaxel

Related Videos

Hope S. Rugo, MD, on Triple-Negative Breast Cancer: Trial Update on Pembrolizumab Plus Olaparib vs Pembrolizumab Plus Chemotherapy

Aditya Bardia, MD, MPH, on Early-Stage, High-Risk Breast Cancer: New Data on Pembrolizumab Plus Chemotherapy

Amy Tiersten, MD, on Metastatic Breast Cancer: A Possible Chemotherapy-Free Front-Line Regimen

Daniel Kates-Harbeck, MD Candidate, and Nadia Harbeck, MD, PhD, on Personalizing Breast Cancer Management With AI: Novel Approach to Predicting Outcomes

Senthil Damodaran, MD, PhD, on Locally Advanced or Metastatic Breast Cancer: Phase II Results on Futibatinib

Hypofractionation vs Conventional Fractionation in Patients With Breast Cancer Planning Breast Reconstruction

Rates of Breast, CRC Screenings Almost Four Times Higher Than Lung Cancer Screenings

Comparing Biopsy Techniques for Prostate Cancer Detection

Characteristics of Nasopharyngeal Carcinoma in the United States

Grocery Store Choice Could Impact Obesity Related Cancer Mortality